American College of Cardiology

American College of Cardiology

Source:

Ezekowitz JA, et al. Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials. Presented at: American College of Cardiology Scientific Session; April 2-4, 2022; Washington, D.C. (hybrid meeting).

Disclosures: Ezekowitz reports receiving research grants from American Regent, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb/Pfizer, eko.ai, US2.ai, Merck, Novartis, Otsuka, Sanofi and Servier, and consulting fees from American Regent, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb/Pfizer, Merck, Novartis, Otsuka, Sanofi and Servier.
April 02, 2022
2 min read
Save

Low-salt dietary intervention did not lower hospitalizations, death: SODIUM-HF

Source:

Ezekowitz JA, et al. Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials. Presented at: American College of Cardiology Scientific Session; April 2-4, 2022; Washington, D.C. (hybrid meeting).

Disclosures: Ezekowitz reports receiving research grants from American Regent, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb/Pfizer, eko.ai, US2.ai, Merck, Novartis, Otsuka, Sanofi and Servier, and consulting fees from American Regent, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb/Pfizer, Merck, Novartis, Otsuka, Sanofi and Servier.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

WASHINGTON — A dietary intervention to reduce sodium intake did not reduce clinical events in ambulatory patients with HF, although researchers saw a modest benefit in quality of life measures, data from the SODIUM-HF trial show.

Justin Ezekowitz

“Patients and their clinicians should have realistic expectations of the benefits of lowering dietary sodium,” Justin Ezekowitz, MB, BCH, MSc, FRCPC, FACC, FAHA, FESC, told Healio at the American College of Cardiology Scientific Session where the data were presented. “Guidelines should consider this information as the largest and longest trial of its type.”

spilled salt
Source: Adobe Stock

For SODIUM-HF, Ezekowitz, who is professor of medicine in the division of cardiology, director of cardiovascular research and co-director of the Canadian VIGOUR Centre at the University of Alberta, and colleagues analyzed data from 806 adults in six countries with chronic HF (NYHA functional class II and III) and receiving optimally tolerated guideline-directed medical treatment from March 2014 to December 2020. The median age of participants was 67 years and 33% were women. Researchers randomly assigned participants to a low-sodium diet of less than 1,500 mg/day or usual care. The primary outcome was a composite of CV-related hospitalization, CV-related ED visits or all-cause death within 12 months.

The findings were simultaneously published in The Lancet.

From baseline to 12 months, median sodium intake decreased from 2,286 mg/day to 1,658 mg/day in the low-sodium group and from 2,119 mg/day to 2,073 mg/day in the usual care group.

By 12 months, primary outcome events occurred in 15% and 17% of participants in the low-sodium and usual care groups, respectively (HR = 0.89; 95% CI, 0.63-1.26; P = .53).

Other outcomes were similar between groups. All-cause death occurred in 6% and 4% of participants in the low-sodium and usual care groups, respectively (HR = 1.38; 95% CI, 0.73-2.6; P = .32), whereas CV-related hospitalization occurred in 10% and 12% of the low-sodium and usual care groups, respectively (HR = 0.82; 95% CI, 0.54-1.24; P = .36).

CV-related ED visits occurred in 4% of participants in both groups (HR = 1.21; 95% CI, 0.6-2.41; P = .6).

No safety events related to the study treatment were reported in either group.

“Clinical research should build off of this work and consider different populations, situations, and degree of sodium reduction and consider these for the topic of future clinical trials,” Ezekowitz told Healio.

Reference: